<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671994</url>
  </required_header>
  <id_info>
    <org_study_id>GOAT</org_study_id>
    <nct_id>NCT02671994</nct_id>
  </id_info>
  <brief_title>Geriatric and Oncologic Assessment Before Treatment</brief_title>
  <acronym>GOAT</acronym>
  <official_title>Significance of Geriatric Assessment for Optimal Treatment of Older Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a randomized controlled trial, the investigators wish to investigate, if oncologic
      treatment decision based on G8 screening followed by geriatric assessment and subsequent MDT,
      if needed, in older frail patients with gynaecologic and urologic cancer is superior to
      standard assessment (PS and clinical assessment) in oncologic treatment decision.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of planned oncologic treatment (number of participants, who complete the planned oncologic treatment)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>A (experimental group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oncologic treatment decision based on G8 screening followed by geriatric assessment and subsequent MDT, if needed, in addition to standard assessment (ECOG Performance Status + clinical assessment).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (control group)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Oncologic treatment decision based on standard assessment (ECOG Performance Status + clinical assessment).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>G8 screening</intervention_name>
    <arm_group_label>A (experimental group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Geriatric assessment</intervention_name>
    <arm_group_label>A (experimental group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically verified gynaecologic cancer (ovarian, uterine, or cervical cancer) or
             urologic cancer (prostate, bladder, or kidney cancer).

          -  Suited for first line medical oncologic treatment with chemotherapy and/or targeted
             therapy.

          -  Age ≥ 70 years.

          -  Understands, speaks, and writes Danish.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Previous cancer diagnosis except for carcinoma in situ of the cervix or skin cancer
             other than malignant melanoma.

          -  Previous chemotherapy and/or targeted therapy for current cancer diagnosis.

          -  Previous radiation therapy or concomitant radiotherapy for current cancer diagnosis.

          -  Surgery within the last 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jørn Herrstedt, MD, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sambavy Nadaraja, MD</last_name>
    <phone>+45 6541 1228</phone>
    <email>sambavy.nadaraja@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jørn Herrstedt, MD, DMSc</last_name>
      <phone>+45 6541 3634</phone>
      <email>herrstedt@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Sambavy Nadaraja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jørn Herrstedt, MD, DMSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars Matzen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Trine L Jørgensen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2016</study_first_submitted>
  <study_first_submitted_qc>January 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Sambavy Nadaraja</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <keyword>Geriatric Assessment</keyword>
  <keyword>G8 screening</keyword>
  <keyword>Oncologic treatment</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

